Phase 2 N=17 LSA4 Protocol for the Treatment of Advanced Pediatric and Adolescent Non-Hodgkins Lymphoma
Non-Hodgkin's Lymphoma
Primary: Complete Remission — 10 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=42 Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma
Recurrent B-Cell Childhood Acute Lymphoblastic Leukemia · Recurrent Childhood B-Lymphoblastic Lymphoma
Primary: 3-year Overall Survival Rate of Patients With Relapsed ALL — 94.4; 55.5; 72.63 percentage of participants — p=0.035
N/A N=89 Vaccine Immune Recovery After Leukemia
Acute Lymphoblastic Leukemia, Pediatric
Primary: Incident Infection Rate in Participants During the First Year Post-acute Lymphoblastic Leukemia Therapy — 3.60 Events per person-year
Phase 2 N=23 NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma
Lymphoblastic Lymphoma
Primary: Probability of Event-free Survival (EFS) — 91.7; 71.4; 100; 86.96 percentage of event-free patients
Phase 2 N=29 Lenalidomide in Treating Patients With High Risk Acute Myeloid Leukemia in Remission
Alkylating Agent-Related Acute Myeloid Leukemia · Secondary Acute Myeloid Leukemia
Primary: Relapse-free Survival (RFS) — 21.5 Months
Phase 2 N=120 Augmented Berlin-Frankfurt-Munster (BFM) Therapy for Adolescent/Young Adults With Acute Lymphoblastic Leukemia or Acute Lymphoblastic Lymphoma
Lymphoblastic Leukemia · Lymphoblastic Lymphoma
Primary: 3-Year Event-Free Survival (EFS) — 68 Participants
Phase 2 N=16 Tositumomab and Iodine I 131 Tositumomab in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in First Remission
Lymphoid Leukemia in Remission · Stage I Chronic Lymphocytic Leukemia · Stage II Chronic Lymphocytic Leukemia
Primary: Probability of Progression-free Survival (PFS) — 52 percentage probability
Phase 2 N=33 Lenalidomide in Chronic Lymphocytic Leukemia (CLL) Patients With Residual Disease
Chronic Lymphocytic Leukemia
Primary: Improvement in Quality of Remission: Number of Participants With Response Versus No Response by NCI Working Group Criteria Disease Status Change at Start/End of…
Phase 1 N=21 Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma
ALL · B Cell Lymphoma · Leukemia
Primary: Number of Participants Who Received Preparative Chemotherapy Followed by Cluster of Differentiation (CD)19-Chimeric Antigen Receptor (CAR): CD19 CAR T-cells With < Grade…
Phase 2 N=43 A Study of Withdrawal of Immunosuppression and Donor Lymphocyte Infusions Following Allogeneic Transplant for Pediatric Hematologic Malignancies
Acute Leukemia · Acute Myeloid Leukemia · Acute Lymphoblastic Leukemia
Primary: Relapse at 2 Years Post-transplant. — 6; 4 participants
Phase 3 N=498 Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia
Lymphoblastic Leukemia, Acute
Primary: Overall Event-free Survival (EFS) — 87.3 Percentage of Participants
Phase 2 N=15 Immunotherapy for Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Blast Phase Chronic Myelogenous Leukemia (BP CML), and Myelodysplastic Syndrome (MDS) Relapse After Allogeneic Transplantation
Leukemia
Primary: Efficacy of GM-CSF and Pegylated Interferon-alpha 2b When Administered to Patients With AML, ALL, Blast Phase CML, and MDS Relapse After Allogeneic Transplantation…
Phase 2 N=8 Maintenance Lenalidomide in Lymphoma
Lymphoma
Primary: Number of Subjects With Dose-limiting Toxicities — 0 Participants
Phase 1 N=40 LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma
Hodgkin Disease · Non Hodgkin Lymphoma · Lymphoepithelioma
Primary: Dose Limiting Toxicity (DLT) Rate by the NCI Common Toxicity Criteria (CTCAE) v2.0 and the Method of Przepiorka et al (Protocol Appendix I) — 0; 0; 0; 0 proportion of…
Phase 2 N=116 Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)
Recurrent Childhood Acute Lymphoblastic Leukemia
Primary: Remission Re-induction (CR2) Rate — .646; .660 proportion of participants
Phase 2 N=15 Nivolumab in AML in Remission at High Risk for Relapse
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome · Adult Acute Myeloid Leukemia in Remission · Blasts Under 10 Percent of Bone Marrow Nucleated Cells
Primary: Recurrence-free Survival Rate — 8.5 Months
Phase 2 N=45 Blinatumomab in Adults With Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic Leukemia
Relapsed/Refractory Philadelphia Positive B-precursor ALL
Primary: Percentage of Participants With Complete Remission/Complete Remission With Partial Hematological Recovery (CR/CRh*) During the First Two Treatment Cycles — 35.6…
Phase 2 N=29 Alemtuzumab (Campath) to Treat T-Large Granular Lymphocyte Leukemia
T-LGL Lymphoproliferative Disorders
Primary: Number of Participants With Hematological Response After Three Months of Alemtuzumab — 15 Participants
Phase 2 N=43 CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma
Primary Mediastinal B-cell Lymphoma · Diffuse, Large B-cell Lymphoma · Diffuse Large B-Cell Lymphoma Transformed From Follicular Lymphoma
Primary: Number of Participants With a Response Assessed by the Response Criteria for Malignant Lymphoma — 2; 3; 2; 3 Participants
Phase 2 N=20 Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in AML Patient Not Eligible for Transplant
Acute Myeloid Leukemia
Primary: Number of Patients With 2-year Relapse Risk — 10 Participants
Phase 2 N=15 Anti-Tac(Fv)-PE38 (LMB-2) to Treat Chronic Lymphocytic Leukemia
Leukemia · Lymphocytic · Chronic
Primary: Response Rate — 0; 1; 3; 11 Participants
Phase 2 N=23 Rituximab to the Preparative Regimen of Etoposide and Total Body Irradiation in Acute Lymphoblastic Leukemia
Leukemia
Primary: Progression-free Survival (PFS) — 4.3; 14.5 Months
N/A N=168 Combination Chemotherapy and Radiation Therapy in Treating Patients With Acute Lymphoblastic Leukemia That Has Relapsed in the CNS or Testes
Leukemia
Primary: Event-free Survival — 64.9; 70 percentage of participants
N/A N=39 Donor Lymphocyte Infusion in Treating Patients With Recurrent or Persistent Hematologic Cancer After Donor Stem Cell Transplant
Leukemia · Lymphoma · Multiple Myeloma and Plasma Cell Neoplasm
Primary: Complete Remission Rate — 8; 6 Participants
Phase 2 N=73 Phase I/IIA Study of CART19 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma
B Cell Leukemia · B Cell Lymphoma
Primary: Number of Subjects With Study Related Adverse Events. — 59 Participants
Phase 2 N=94 Treatment and Natural History Study of Lymphomatoid Granulomatosis
Lymphomatoid Granulomatosis · Granulomatosis, Lymphomatoid · Non-Hodgkins Lymphoma
Primary: Overall Response Rate (ORR) — 53.45; 51.85; 57.14; 50.00 percentage of participants
Phase 3 N=9,350 Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma
Acute Lymphoblastic Leukemia · Adult B Lymphoblastic Lymphoma · Ann Arbor Stage I B Lymphoblastic Lymphoma
Primary: Disease Free Survival (DFS) in Average Risk (AR) Patients Based on the Methotrexate Dose Randomization — 95.05; 94.17 percent probability
Phase 2 N=18 Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder
EBV-Related Post-Transplant Lymphoproliferative Disorder · Monomorphic Post-Transplant Lymphoproliferative Disorder · Polymorphic Post-Transplant Lymphoproliferative Disorder
Primary: Percentage of Patients Assigned to Arm Latent Membrane Protein-specific T-cells (LMP-TC) With Successful LMP-specific T Cell Product Match, Were Treated Within Two Weeks…
Phase 2 N=30 Phase II Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Chronic Lymphocytic Leukemia · CLL
Primary: Overall Response Rate (ORR) — 25 Participants
Phase 2 N=296 Therapy for Pediatric Hodgkin Lymphoma
Hodgkin Lymphoma
Primary: Event-free Survival Probability by Risk Group — 0.886; 0.844; 0.667; 0.793 probability of 5 yr. event free survival